A Breakthrough in Stroke Science

PSE.SR.screenshot  PSE.SR.p3 

Learn more. Please read our published scientific articles (article 1article 2; article 3). This is emerging science that takes years to achieve widespread scientific consensus. The scientific rationale is supported by published, scientific articles co-authored by independent academic scientists (article 1; article 2). Read news stories (article 1, article 2) about others we have helped.

For more information, or to schedule an appointment for screening or consultation, please call the INR in California directly at (310) 479-0107 or in Florida at (561) 353-9707.

The INR is pleased to make this therapeutic approach available for selected patients. Individual results vary, not all patients respond. Treatment is an innovative off-label patented invention of the INR. Additional doses may be needed for optimal benefit, please see the Terms of Use. These unprecedented clinical results rely upon the Institute’s patented TransBarrier® drug delivery methodology, covered by multiple issued and pending U.S. and international patents, including U.S. patents 6419944, 6537549, 7214658, 7629311, 8119127, and 8236306, assigned to TACT IP, LLC and Australian patent 758,523. See the following published, peer-reviewed articles: